Slide 1 2016 Immunization Update for Pharmacists Miranda Wilhelm, Pharm.D. Clinical Associate Professor Southern Illinois University Edwardsville School of Pharmacy Slide 2 Disclosure Miranda Wilhelm reports: Speaker s bureau member for Merck Vaccines CEI has taken appropriate action for conflict resolution, including external peer review by an un-conflicted reviewer. Slide 3 Learning Objectives Upon successful completion of this activity, pharmacists should be able to: Discuss the 2016 Advisory Committee on Immunization Practices (ACIP) recommendations regarding adult and pediatric immunizations. Identify true contraindications to receipt of a variety of vaccines. Review influenza vaccine considerations such as nomenclature, characteristics, schedule, contraindications, and precautions in preparation for the 2016-2017 season. Evaluate a patient s immunization history to determine appropriate vaccine recommendations based on the appropriate immunization schedule.
Slide 4 Summary of ACIP Recommendations 2015 Use of Serogroup B Meningococcal Vaccines in Persons Aged 10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices. Update: Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. Slide 5 Summary of ACIP Recommendations 2016 Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses Recommendations of the Advisory Committee on Immunization Practices, 2015. Slide 6 Use of Serogroup B Meningococcal Vaccines in Persons Aged 10 Years at Increased Risk Citation Use of Serogroup B Meningococcal Vaccines in Persons Aged 10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR, June 12, 2015; 64(22): 608-612. Summary What is currently recommended? Why are the recommendations being modified now? What are the new recommendations? Recommendation Provides recommendation for persons at increased risk for meningococcal disease and should receive the MenB vaccine Those 10 years of age with complement component deficiencies; anatomic or functional asplenia; microbiologist routinely exposed to isolates of Neisseria meningitides; and increased risk due to a serogroup B meningococcal disease outbreak
Slide 7 FDA approved October 29, 2014 (Pfizer) First serogroup B meningococcal vaccine Approved for patients 10 to 25 years of age 3-dose series, IM, 0.5 ml dose administered at 0, 2 and 6-months apart April 14, 2016 FDA Update: Two-dose schedule (administered at 0 and 6 months) Modification of 3-dose schedule (0, 1-2 and 6 months) MMWR, June 12, 2015; 64(22): 608-612. Trumenba [package insert]. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm421139.pdf. Accessed June 23, 2016. Accelerated Supplement Approval Letter. Department of Health and Human Services. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm496391.pdf. Accessed June 23, 2016. Slide 8 FDA approved January 23, 2015 (Novartis) Second serogroup B meningococcal vaccine Approved for patients 10 to 25 years of age 2-dose series, IM, 0.5 ml dose administered at least 1 month apart Bexsero [package insert]. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm431447.pdf. Accessed June 23, 2016. Slide 9 Yellow Fever Vaccine Booster Doses Citation Summary Recommendation Yellow Fever Vaccine What is currently Update of yellow fever Booster Doses: recommended? vaccine recommendations Recommendations of the in relation to World Health Advisory Committee on Why are the Organization Strategic Immunization Practices, recommendations being Advisory Group of Experts 2015. modified now? in Immunization MMWR, June 19, 2015; recommendations 64(23): 647-650. Single primary dose of What are the new yellow fever vaccine recommendations? provides long-lasting protection and is adequate for most travelers 10-year booster dose requirement is no longer relevant Consideration and recommendations for booster doses for certain travelers and laboratory workers
Slide 10 Intervals Between PCV13 and PPSV23 Vaccines Citation Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices. MMWR, September 4, 2015; 64(34): 818-825. Summary What is currently recommended? Why are the recommendations being modified now? What are the new recommendations? Recommendation Harmonized the dosing interval All patients at 65 years of age should receive 1 dose of PCV13 followed 1 year later by 1 dose of PPSV23 Slide 11 Intervals Between PCV13 and PPSV23 Vaccines MMWR, September 4, 2015; 64(34): 944-947. Slide 12 Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers Citation Update: Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B- Infected Mothers. MMWR, October 9, 2015; 64(39):1118-1120. Summary What recommendations are being reviewed? Why are the recommendations being reviewed now? What is the new recommendation? Recommendation Not ACIP statement but related document from CDC For infants born to hepatitis B-infected mothers, postvaccination serologic testing should be completed at age 9-12 months (or 1-2 months after final dose of the vaccine series)
Slide 13 Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers MMWR, October 9, 2015; 64(39): 1118-1120. Slide 14 Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults Citation Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR, October 23, 2015; 64(41): 1171-1176. Summary What is currently recommended? Why are the recommendations being modified now? What are the new recommendations? Recommendation All adolescents aged 11 or 12 years should receive 1- dose of meningococcal conjugate vaccine (MenACWY) with a booster dose at age 16. MenB vaccine series may be administered to adolescents and young adults 16-23 years. Preferred for 16-18 years. Slide 15 Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults Age at MenB series Cases prevented MMWR, October 23, 2015; 64(41): 1171-1176. Deaths prevented NNV to prevent case NNV to prevent death Cost per QALY (million $) 11 yrs 15 2 203,000 1,512,000 8.7 16 yrs 28 5 107,000 788,000 4.1 18 yrs 29 5 102,000 638,000 3.7 College student 9 1 368,000 2,297,000 9.4
Slide 16 Testing Your Knowledge True/False Meningococcal serogroup B vaccination is recommended for adolescents and young adults with a preference of 16 to 18 years of age. a) True b) False Slide 17 Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel Citation Use of Vaccinia Virus Smallpox Vaccine in Laboratory and Health Care Personnel at Risk for Occupational Exposure to Orthopoxviruses Recommendations of the Advisory Committee on Immunizaiton Practices, 2015. MMWR, March 18, 2016; 65(10): 257-262. Summary What is currently recommended? Why are the recommendations being modified now? What are the new recommendations? Recommendation Routine vaccination with ACAM2000 is recommended for laboratory personnel who directly handle Cultures or Animals contaminated or infected with vaccinia virus Health care personnel who treat patients with vaccinia virus or administer ACAM2000 vaccine can be offered vaccination Slide 18 Vaccine Storage and Handling Toolkit Updated June 2016 Adjusted CDC guidance on Fahrenheit temperature range for storing refrigerated vaccines NEW = 36⁰F - 46⁰F OLD = 35⁰F - 46⁰F Celsius remains unchanged (2⁰C - 8⁰C) Vaccine Storage and Handling Toolkit. CDC Website. Available at: http://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html. Accessed 7/11/16.
Slide 19 Screening for Contraindications Slide 20 1. Is the child sick today? 2. Does the child have allergies to medications, food, a vaccine component, or latex? 3. Has the child had a serious reaction to a vaccine in the past? 4. Has the child had a health problem with lung, heart, kidney or metabolic disease, asthma, or a blood disorder? Is he/she on long-term aspirin therapy? 5. If the child to be vaccinated is 2 through 4 years of age, has a health care provider told you that the child had wheezing or asthma in the past 12 months? 6. If your child is a baby, have you ever been told he or she has had intussusception? 7. Has the child, a sibling, or a parent had a seizure; has the child had a brain or other nervous system problems? 8. Does the child have cancer, leukemia, HIV/AIDS, or any other immune system problem? 9. In the past 1-3 months, has the child taken medications that affect the immune system such as prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn s disease, or psoriasis; or had radiation treatments? 10. In the past year, has the child received a transfusion of blood or blood products, or been given immune globulin or an antiviral drug? 11. Is the child/teen pregnant or is there a chance she could become pregnant during the next month? 12. Has the child received vaccinations in the past 4 weeks? Slide 21 1. Is the child sick today? No evidence that acute illness reduces vaccine efficacy or increases vaccine-related adverse events Mild illnesses (otitis media, upper respiratory infection, and diarrhea) are NOT contraindications Antibiotics are NOT a contraindication Precaution moderate or severe acute illness, all vaccines should be delayed MMWR, January 28, 2011; 60(2): 1-64.
Slide 22 2. Allergies to medications, food? Must be anaphylaxis and not an intolerance Medications Neomycin DTaP, Hep A, Influenza (Afluria, Fluvirin), MMR, MMRV, IPV, Varicella, Zoster Food Gelatin MMR, MMRV or Varicella Eggs Influenza? Vaccine component Latex Varies vial or syringe tip cap Pink Book Appendix B. Vaccine Excipient & Media Summary. CDC Website. Available at:. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/excipient-table-2.pdf. Accessed 12/10/15 Slide 23 3. Serious reaction in the past? History of anaphylactic reaction to a previous dose or vaccine component History of encephalopathy within 7 days following pertussis-containing vaccine Precautions for DTaP include: Seizure within 3 days of a dose Pale or limp episode or collapse within 48 hours of a dose Continuous crying for 3 or more hours within 28 hours of a dose Fever of 105⁰F within 48 hours of a dose Screening Checklist for contraindications to Vaccines for Children and Teens. Immunization Action Coalition Website. Available at: http://www.immunize.org/catg.d/p4060.pdf. Accessed 12/10/15 Slide 24 4. Health problem or aspirin therapy? Safety of Live Attenuated Influenza Vaccine (LAIV) has not been established for patients with medical conditions Risk of Reye s Syndrome when aspirin and live attenuated vaccines are administered concomitantly Screening Checklist for contraindications to Vaccines for Children and Teens. Immunization Action Coalition Website. Available at: http://www.immunize.org/catg.d/p4060.pdf. Accessed 12/10/15.
Slide 25 5. Wheezing in a 2 to 4 year old? Increased risk of wheezing following administration of LAIV Not listed in package insert ACIP recommends children 2 through 4 years of age with wheezing in the past 12 months receive IIV MMWR, August 7, 2015; 64(30):821. Slide 26 6. History of intussusception? History of intussusception is a contraindication for rotavirus vaccine Screening Checklist for contraindications to Vaccines for Children and Teens. Immunization Action Coalition Website. Available at: http://www.immunize.org/catg.d/p4060.pdf. Accessed 12/10/15. Slide 27 7. Seizure or nervous system problem? History of encephalopathy within 7 days following pertussis-containing vaccine History of seizures unrelated to vaccination with MMRV. Should receive separate MMR and VAR vaccines. Precaution with history of Guillain-Barre syndrome (GBS) with the following: Td/Tdap: if GBS occurred within 6 weeks of prior tetanuscontaining vaccine Influenza: if GBS occurred within 6 weeks of prior dose Screening Checklist for contraindications to Vaccines for Children and Teens. Immunization Action Coalition Website. Available at: http://www.immunize.org/catg.d/p4060.pdf. Accessed 12/10/15.
Slide 28 8. Current immune system problem? Live virus vaccines are usually contraindicated in immunocompromised patients LAIV inactivated vaccines are available MMR can be used for HIV-infected children if no evidence of immunosuppression VAR can be used for HIV-infected children if CD4 T-lymphocyte percentage at 15% or greater OR in those 8 years and older if CD4 count is 200 cells/µl RV severe combined immunodeficiency (SCID), other forms of immunosuppression are precautions MMWR, January 28, 2011; 60(2):1-64. Slide 29 9. Immune suppressing medication? Live virus vaccines are usually contraindicated in immunocompromised patients and should be postponed until after chemotherapy or high-dose steroid therapy High-Level Low-Level Receiving cancer chemotherapy Receiving a lower daily dose of corticosteroid therapy for > 14 Within 2 months after solid organ days transplantation Receiving methotrexate (MTX) Receiving daily corticosteroid 0.4 mg/kg/week, azathioprine 3 therapy with a dose of 20 mg of mg/kg/day, or 6-mercaptopurine prednisone for > 14 days 1.5 mg/kg/day Receiving certain biologic immune modulators (TNF-α blockers) Clin Infect Dis 2014 Feb; 58(3):e44-100. Slide 30 10. Blood transfusion? Certain live virus vaccines may have reduced efficacy when administered concurrently with blood products or antiviral drugs and need to be deferred Screening Checklist for contraindications to Vaccines for Children and Teens. Immunization Action Coalition Website. Available at: http://www.immunize.org/catg.d/p4060.pdf. Accessed 12/10/15.
Slide 31 Pink Book Appendix A. Recommended intervals between administration of immune globulin preparations and measlesor varicella-containing vaccine. CDC Website. Available at:. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/mmr_ig.pdf. Accessed 12/11/15. Slide 32 11. Is the child/teen pregnant? Live virus vaccines are contraindicated one month before and during pregnancy because of the theoretical risk of virus transmission to the fetus LAIV inactivated vaccines available MMR congenital rubella syndrome MMRV congenital rubella syndrome or varicella syndrome VAR congenital varicella syndrome IPV theoretical concerns MMWR, January 28, 2011; 60(2):1-64. Slide 33 Immunization and Pregnancy. CDC Website. Available at:. http://www.cdc.gov/vaccines/pubs/downloads/f_preg_chart.pdf
Slide 34 12. Other vaccines in the past 4 weeks? Live virus vaccines when not administered on the same day need to be separated by 28 days Inactivated vaccines may be given at the same time or at any spacing interval MMWR, January 28, 2011; 60(2):1-64. Slide 35 Summary of Contraindications All vaccines Severe allergic reaction (anaphylaxis) after a previous dose or to a vaccine component Live attenuated vaccines Pregnancy History of intussusception Rotavirus Severe combined immunodeficiency (SCID) - Rotavirus Known severe immunodeficiency MMR, VAR, Zoster Inactivated vaccines Encephalopathy within 7 days of administration Pertussis-containing vaccine Age younger than 6 weeks - Hib Pink Book Appendix A. Guide to Contraindications and Precautions to Commonly Used Vaccines. CDC Website. Available at:. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/a/contraindications.pdf. Accessed 12/10/15. Slide 36 Influenza Influenza season is October to May and commonly peaks in January to February Annual influenza vaccination is recommended for all persons 6 months of age and older
Slide 37 Testing Your Knowledge What volume of inactivated influenza vaccine is administered intramuscularly to an adult patient? a) 0.1 ml b) 0.25 ml c) 0.5 ml d) 1 ml Slide 38 Nomenclature for Influenza Vaccine Inactivated Influenza Vaccine (IIV) Trivalent inactivated influenza vaccine (IIV3) Quadrivalent inactivated influenza vaccine (IIV4) Cell cultured inactivated influenza vaccine (cciiv3) Recombinant hemagglutinin Influenza Vaccine (RIV) N/A Live-attenuated Influenza Vaccine (LAIV) Quadrivalent live-attenuated influenza vaccine (LAIV4) Slide 39 Influenza Algorithm for Children 6 Months to 8 Years MMWR, August 7, 2015; 64(30): 818-825.
Slide 40 Recommendation for Influenza Vaccination with Egg Allergy MMWR, August 15, 2014; 63(327):691-697. Slide 41 Influenza Vaccination of Persons with Egg Allergy Proposed recommendations for 2016-2017: LAIV included as an option for individuals with egg allergy of any severity Removal of 30 minute postvaccination observation period (15 minutes recommended for all persons, particularly adolescents, in case syncope occurs) Persons with a history of severe reaction to eggs should be vaccinated in a medical setting with a physician immediately available Proposed Recommendations 2016-2017 Influenza Season. CDC Website. Available at: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-02/flu-04-grohskopf.pdf. Accessed: 4/8/16. Slide 42 Influenza Contraindications / Precautions IIV (includes IIV3, IIV4 and cciiv) Contraindications History of severe allergic reaction to any component of the vaccine, including egg protein, or after previous dose of any influenza vaccine Precautions Moderate to severe illness with or without fever History of Guillain-Barre syndrome within 6 weeks of receipt of influenza vaccine
Slide 43 Influenza Contraindications / Precautions LAIV Contraindications History of severe allergic reactions to any component of the vaccine, including egg protein, gentamicin, gelatin, and arginine, or after a previous dose of any influenza vaccine Concomitant aspirin therapy in children and adolescents* * These persons should receive IIV In addition, ACIP recommend against use in the following: Children aged < 2 years* Adults aged 50 years* Children 2-4 years with recurrent wheezing or asthma in the preceding 12 months* Persons with asthma* Persons with chronic medical conditions* Persons with immunosuppression* Persons in close contact with severely immunosuppressed patients who require a protected environment* Pregnant women* Slide 44 Influenza Contraindications / Precautions LAIV Precautions Moderate to severe illness with or without fever History of Guillain-Barre syndrome within 6 weeks of receipt of influenza vaccine Drug Interactions Influenza antiviral agents Do not administer vaccine until 48 hours after antiviral use is discontinued Do not administer antiviral agents until 2 weeks after vaccine administration unless medically necessary Slide 45 Testing Your Knowledge Which of the following antiviral agents has a drug interaction with the influenza vaccine and would require separation? a) Acyclovir (Zovirax) b) Oseltamivir (Tamiflu) c) Ritonavir (Norvir) d) Valacyclovir (Valtrex)
Slide 46 Influenza Contraindications / Precautions RIV Contraindications History of severe allergic reaction to any component of the vaccine Precautions Moderate to severe illness with or without fever History of Guillain-Barre syndrome within 6 weeks of receipt of influenza vaccine Slide 47 Seasonal Influenza Vaccines Vaccine Approved Age Indication Inactivated Influenza Vaccine (IIV4) Fluarix Quadrivalent 3 years FluLaval Quadrivalent 3 years Fluzone Quadrivalent 6 months Fluzone Intradermal Quadrivalent 18 to 64 years Inactivated Influenza Vaccine (IIV3) Afluria 9 years needle/syringe 18 to 64 years jet injector Fluvirin 4 years Fluzone (standard dose) 6 months Fluzone High-Dose 65 years Inactivated Influenza Vaccine Cell-Culture (cciiv3) Flucelvax 18 years Recombinant influenza Vaccine (RIV3) Flublok 18 years Live Attenuated Influenza Vaccine (LAIV4) FluMist Quadrivalent 2 to 49 years (healthy, not pregnant) MMWR, August 7, 2015; 64(30): 818-825. Slide 48 ACIP Votes Down Use of LAIV June 22, 2016 ACIP Meeting Poor or lower efficacy of LAIV for children 2 to 17 years from 2103-2016 2015-2016 vaccine effectiveness (VE) for LAIV was 3% 2015-2016 vaccine effectiveness (VE) for IIV was 63% ACIP recommended to NOT use LAIV during the 2016-2017 influenza season This recommendation must be reviewed and approved by the CDC Director ACIP votes down use of LAIV for 2016-2017 flu season. CDC Website. Available at: http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html. Accessed July 13, 2016.
Slide 49 New Influenza Vaccine Fluad, influenza vaccine adjuvanted Approved November 24, 2015 First influenza vaccine approved containing an adjuvant (MF59C.1) Squalene based oil-in-water emulsion Trivalent inactivated influenza vaccine (IIV3) Indicated/approved for 65 years of age and older Efficacy study Fluad induced antibody levels that were comparable to non-adjuvanted vaccine Safety ADEs include injection site pain and tenderness, muscle aches, headache, fatigue FDA approves first seasonal influenza vaccine containing an adjuvant. FDA Website. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm474295.htm. Accessed June 29, 2016. Slide 50 Recommended Influenza Vaccine Composition 2016-2017 A/California/7/2009 (H1N1)pdm09-like virus A/Hong Kong/4801/2014 (H3N2)-like virus B/Brisbane/60/2008-like virus Additional strain for quadrivalent vaccines B/Phuket/3073/2013-like virus Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season. World Health Organization Website. Available at:. http://www.who.int/influenza/vaccines/virus/recommendations/2016_17_north/en/. Accessed 4/8/16. Slide 51 Weekly US Map: Influenza Summary Update. Centers for Disease Control and Prevention Website. Available at: http://www.cdc.gov/flu/weekly/usmap.htm. Accessed 6/9/16.
Slide 52 Click to edit Click to edit Master text styles Second level Third level Fourth level Fifth level http://www.cdc.gov/flu/weekly/#s1 Slide 53 http://www.cdc.gov/flu/weekly/#s1 Slide 54 http://www.cdc.gov/flu/weekly/#s1
Slide 55 Case 1 MD, an 18 year old male, presents to his primary care provider for an annual well visit. He needs documentation of immunizations prior to entering college in the fall. What is the first question that you should ask MD about immunizations? Slide 56 MD s Immunization Record HepB completed series RV completed series DTaP completed series Hib completed series PCV7 x 4 last given at 1 year old IPV completed series Influenza x 10 last given at 8 years old MMR x 2 last given at 5 years old VAR x 2 last given at 5 years old HepA completed series MCV4 x 1 last given at 12 years old Tdap x 1 last given at 12 years old HPV x 2 last given at 12 years old Slide 57 Screening Questionnaire Screening Question Response 1. Are you sick today? No 2. Does the child have allergies to medications, food, a vaccine component, or latex? No 3. Has the child had a serious reaction after receiving a vaccine in the past? No 4. As the child had a health problem with lung, heart kidney or metabolic disease (e.g. diabetes), No asthma, or a blood disorder? Is he/she on long-term aspirin therapy? 5. If the child to be vaccinated is 2 through 4 years of age, has a healthcare provider told you that N/A the child had wheezing or asthma in the past 12 months? 6. If your child is a baby, have you ever been told he or she has had intussusception? N/A 7. Has the child, a sibling, or a parent had a seizure; has the child had brain or other nervous No system problems? 8. Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem? No 9. In the past 3 months, has the child taken medications that affect the immune system, such as No prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn s disease, or psoriasis; or had radiation treatments? 10. In the past year, has the child received a transfusion of blood or blood products, or been given No immune (gamma) globulin or an antiviral drug? 11. Is the child/teen pregnant or is there a chance she could become pregnant during the next N/A month? Has the 12. child received vaccinations in the past 4 weeks? No What vaccinations are recommended for MD?
Slide 58 Schedule for Persons Aged 0 Through 18 Years Slide 59 Case 1 Summary Inactivated influenza vaccine (IIV3/IIV4) OR Live attenuated influenza vaccine (LAIV4) Meningococcal conjugate vaccine (MCV4) Human papillomavirus vaccine (HPV9) Meningococcal serogroup B vaccine Slide 60 Case 2 AW is a 32 year old female with Type 1 diabetes who presents to the community pharmacy for a refill of her prenatal vitamin and insulin prescriptions. She is 32 weeks pregnant. She notices the pharmacy's immunization clinic sign and remembers her OB/GYN mentioned she should get a couple of vaccinations. What is the first question that you should ask AW about immunizations?
Slide 61 AW s Immunization Record Up-to-date at 11 to 12 year old well child visit No immunizations since Slide 62 Screening Questionnaire Screening Question Response 1. Are you sick today? No 2. Do you have allergies to medications, food, a vaccine component, or latex? No 3. Have you ever had a serious reaction after receiving a vaccination? No 4. Do you have a long-term health problem with heart disease, lung disease, asthma, kidney No disease, metabolic disease (e.g. diabetes), anemia, or other blood disorder? 5. Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem? No 6. In the past 3 months, have you taken medications that affect your immune system, such as No prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn s disease, or psoriasis; or have you had radiation treatments? 7. Have you had a seizure or a brain or other nervous system problem? No 8. During the past year, have you received a transfusion of blood or blood products, or been No given immune (gamma) globulin or an antiviral drug? 9. For women: Are you pregnant or is there a chance you could become pregnant during the YES next month? 10. Have you received any vaccinations in the past 4 weeks? No What vaccinations are recommended for AW? Slide 63 Schedule for Adults By Medical or Other Indication
Slide 64 Case 2 Summary Inactivated influenza vaccine (IIV3/IIV4) Tetanus-diphtheria-acellular pertussis vaccine (Tdap) Hepatitis B vaccine Pneumococcal polysaccharide vaccine (PPSV23) Slide 65 Case 3 NS, a 66 year old male, presents to the community pharmacy for his annual influenza vaccine. What is the first question that you should ask NS about immunizations? Slide 66 NS s Immunization Record Influenza yearly x 10 years Unsure of childhood immunizations
Slide 67 Screening Questionnaire Screening Question Response 1. Are you sick today? No 2. Do you have allergies to medications, food, a vaccine component, or latex? YES 3. Have you ever had a serious reaction after receiving a vaccination? No 4. Do you have a long-term health problem with heart disease, lung disease, asthma, kidney No disease, metabolic disease (e.g. diabetes), anemia, or other blood disorder? 5. Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem? No 6. In the past 3 months, have you taken medications that affect your immune system, such as No prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn s disease, or psoriasis; or have you had radiation treatments? 7. Have you had a seizure or a brain or other nervous system problem? No 8. During the past year, have you received a transfusion of blood or blood products, or been No given immune (gamma) globulin or an antiviral drug? 9. For women: Are you pregnant or is there a chance you could become pregnant during the N/A next month? 10. Have you received any vaccinations in the past 4 weeks? No What vaccinations are recommended for NS? Slide 68 Schedule for Adults by Age Slide 69 Latex Allergy What do we do? Fluzone Package Insert Boostrix Package Insert Zostavax Package Insert Not listed in package insert (need to call manufacturer) Prevnar 13 Package Insert
Slide 70 Case 3 Summary Inactivated influenza vaccine (IIV3/IIV4) Tetanus-diphtheria-acellular pertussis vaccine (Tdap) Zoster vaccine Pneumococcal conjugate vaccine (PCV13) One year later Pneumococcal polysaccharide vaccine (PPSV23) Slide 71 CPE Instructions Logon to www.gotocei.org Click on My Profile Claim CPE. If the activity title is under PENDING, please move to TO DO. From TO DO, locate the activity title you wish to complete, and click on Exam. There is no code associated with this activity. All participants were to have pre-registered on the CEI website. Once your credit has been claimed, the activity will move to your Completed Activities. Complete the Exam and Evaluation as prompted. Click SUBMIT to send your information to CPE Monitor.